Effectivity and safety of TAF in CHB patients with concurrent MASLD: a real-world study.

BMC Gastroenterol · 2026 · PMC13321476 · PMID 42104239

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Conclusion TAF treatment in treatment-naïve CHB patients with MASLD effectively suppressed viral replication, showed a trend toward improving liver stiffness, and has no adverse effects on lipid profiles or renal function.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.